Pulmonary Arterial Hypertension in Systemic Sclerosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by IRCCS Policlinico S. Matteo.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
IRCCS Policlinico S. Matteo
ClinicalTrials.gov Identifier:
NCT00617487
First received: February 6, 2008
Last updated: August 3, 2009
Last verified: August 2009

February 6, 2008
August 3, 2009
December 2007
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00617487 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Pulmonary Arterial Hypertension in Systemic Sclerosis
Stress Echocardiography in the Early Identification of Pulmonary Arterial Hypertension in Systemic Sclerosis

The purpose of this study is to evaluate the role of stress echocardiography, compared to standard echocardiography in the early identification of pulmonary arterial hypertension in systemic sclerosis. To evaluate the role of BNP in this setting.To analyze data recorded with respect to the parameters commonly used for SSc evaluation (eg thorax HRCT, pulmonary function tests + DLCO, nailfold capillaroscopy, etc); these parameters are available starting for 1999.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

patients with systemic sclerosis

  • Systemic Sclerosis
  • Pulmonary Arterial Hypertension
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
January 2010
Not Provided

Inclusion Criteria:

  • Patients with systemic sclerosis according to LeRoy criteria

Exclusion Criteria:

  • Pregnancy
  • Significant valvular disease
  • Low left ventricular function upon echocardiography (ejection fraction<55%)
  • History of atrial fibrillation, myocardial infarction, pulmonary thromboembolisms, neoplasia or severe hepatic disease.
Both
18 Years to 90 Years
No
Contact: Lorenzo Cavagna, MD 00390382501878 lorenzo.cavagna@unipv.it
Italy
 
NCT00617487
EchostressSSc
Yes
Dr Ghio Stefano, Cardiology Unit IRCCS Foundation Policlinico S. Matteo, Pavia
IRCCS Policlinico S. Matteo
Not Provided
Study Director: Stefano Ghio, MD IRCCS Foundation Policlinico S. Matteo, Cardiology
Principal Investigator: Lorenzo Cavagna, MD University and IRCCS Foundation Policlinico S. Matteo, Rheumatology
IRCCS Policlinico S. Matteo
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP